Acta Scientific Clinical Case Reports

Case Report Volume 2 Issue 1

Asymptomatic Hyponatremia Revealing Inappropriate Secretion of ADH Syndrome In a Patient with Triple A Syndrome

Mrabet Houcem Eomma*

Endocrinology Department, Tahar Sfar CHU, Mahdia, Tunisia

*Corresponding Author: Mrabet Houcem Eomma, Endocrinology Department, Tahar Sfar CHU, Mahdia, Tunisia.

Received: November 24, 2020; Published: December 09, 2020

×

Abstract

Context: Allgrove’s syndrome or triple A syndrome (AAA), combines Addison’s disease with alacrimia and achalasia. In this context, hyponatremia would suggest acute adrenal insufficiency and initiate replacement therapy. However, other etiologies are possible including SIADH. To the best of our knowledge, this combination of Syndrome 3A and SIADH has not been reported.

Objectives: Describe the etiological and therapeutic particularities of a rare association between AAA syndrome and SIADH.

Materiel and Methods: We present the case of a patient followed for AAA syndrome and depression, in whom a profound hyponatremia discovered incidentally related to idiopathic SIADH.

Design: a case report of a patient hospitalized in endocrinology department in 2018

Observation: This is a report of a patient whose AAA syndrome was genetically confirmed at the age of 4 years. At 25, she was hospitalized for investigation of asymptomatic hyponatremia at 119 mmol/L. She was receiving 20 mg of hydrocortisone and 100 mcg of fludrocortisone. Olanzapine, added 3 years ago due to behavioral disorders, had already been stopped by the patient for months. The diagnosis of acute adrenal crisis was ruled out. Plasma osmolarity was 243 mosm/L, with inadequate natriuresis at 118 mmol/24 h. The SIADH diagnosis was retained. Natremia was corrected after fluid restriction. The etiological investigation of this SIADH was negative.

Conclusion: The association of SIADH with syndrome 3A requires patient education in order to maintain a satisfactory state of fluid and electrolyte balance. Olanzapine, should not probably be reintroduced in this patient.

Keywords: Allgrove’s Syndrome; Allgrove’s Syndrome or Triple A Syndrome (AAA)

×

References

  1. Pintaldi S., et al. “SIADH versus adrenal insufficiency: a life-threatening misdiagnosis”. Italian Journal of Pediatrics 1 (2019): 23.
  2. Thompson MD., et al. “Severe hyponatraemia with absence of hyperkalaemia in rapidly progressive Addison’s disease”. BMJ Case Report (2015).
  3. Chabre O., et al. “Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality”. Annuals of Endocrinology (Paris)6 (2017): 490-494.
  4. Nasrallah F., et al. “X-linked Adrenoleukodystrophy, The Tunisian Experience”. Clinical Lab10 (2015): 1531-1536.
  5. Sheikh MM and Bittar K. “Allgrove Syndrome”. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2020).
  6. Kallabi F., et al. “Clinical and Genetic Characterization of 26 Tunisian Patients with Allgrove Syndrome”. Archives of Medical Research2 (2016): 105-110.
  7. Derrar R., et al. “Alacrymie congénitale révélant un syndrome d’Allgrove: à propos de trois cas”. Pan African Medical Journal (2015): 20.
  8. Verbalis JG., et al. “Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations”. The American Journal of Medicine 10 (2013): S1-42.
  9. Peri A. “Morbidity and Mortality of Hyponatremia”. Frontiers of Hormone Research 52 (2019): 36-48.
  10. Cuesta M and Thompson CJ. “The syndrome of inappropriate antidiuresis (SIAD)”. Best Practice and Research Clinical Endocrinology and Metabolism 2 (2016): 175-187.
  11. Tee K and Dang J. “The suspect – SIADH”. Australian Family Physician9 (2017): 677-680.
  12. Kinjo T., et al. “Addison’s disease due to tuberculosis that required differentiation from SIADH”. Journal of Infection and Chemotherapy4 (2009): 239-242.
×

Citation

Citation: Mrabet Houcem Eomma. “Asymptomatic Hyponatremia Revealing Inappropriate Secretion of ADH Syndrome In a Patient with Triple A Syndrome". Acta Scientific Clinical Case Reports 2.1 (2021): 11-15.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.278

Indexed In